Article
BCOR and BCORL1 Mutations Drive Epigenetic Reprogramming and Oncogenic Signaling by Unlinking PRC1.1 from Target Genes.
Blood cancer discovery - 1 Mar 2022
Schaefer Eva J, Wang Helen C, Karp Hannah Q, Meyer Clifford A, Cejas Paloma, Gearhart Micah D, Adelman Emmalee R, Fares Iman, Apffel Annie, Lim Klothilda, Xie Yingtian, Gibson Christopher J, Schenone Monica, Murdock H Moses, Wang Eunice S, Gondek Lukasz P, Carroll Martin P, Vedula Rahul S, Winer Eric S, Garcia Jacqueline S, Stone Richard M, Luskin Marlise R, Carr Steven A, Long Henry W, Bardwell Vivian J, Figueroa Maria E, Lindsley R Coleman
Abstract excerpt
Polycomb repressive epigenetic complexes are recurrently dysregulated in cancer. Unlike polycomb repressive complex 2 (PRC2), the role of PRC1 in oncogenesis and therapy resistance is not well-defined. Here, we demonstrate that highly recurrent mutations of the PRC1 subunits BCOR and BCORL1 in leukemia disrupt assembly of a noncanonical PRC1.1 complex, thereby selectively unlinking the RING-PCGF enzymatic core...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.